This randomized , double-blind , placebo-controlled , crossover study evaluated 14 days of once daily , topical intranasal SB-705498 12 mg in 40 patients with NAR using a CDA challenge experimental model in an environmental exposure chamber ( EEC , Cetero Research , Mississauga , Ontario ) .